Hereditary factors account for a significant proportion of breast cancer risk. Approximately
20% of hereditary breast cancers are attributable to pathogenic variants in the highly …

Germline mutations in BRCA1 and BRCA2 (BRCA) genes confer high risk of developing
cancer, especially breast and ovarian tumors. Since the cloning of these tumor suppressor …

Background Mutations in PALB2 predispose to breast cancer, but the effect on prognosis of
carrying a PALB2 mutation has not been ascertained. We aimed to estimate the odds ratio …

Background: Invasive lobular breast cancer (ILC) accounts for approximately 15% of
invasive breast carcinomas and is commonly associated with lobular carcinoma in situ …

PALB2 has taken its place with bona fide breast cancer susceptibility genes. It is now well
established that women who carry loss-of-function mutations in the PALB2 gene are at …

Introduction Ductal carcinoma in situ (DCIS) is a non-obligate precursor of invasive ductal
breast cancer, and approximately 20% of screen-detected tumours are pure DCIS. Most risk …

Abstract Among breast cancers, 10 to 15% of cases would be due to hereditary risk. In these
familial cases, mutations in BRCA1 and BRCA2 are found in only 15% to 20%, meaning that …

Purpose Somatic mutations in TP53 and PIK3CA genes, the two most frequent genetic
alternations in breast cancer, are associated with prognosis and therapeutic response. This …

Background PALB2 has emerged as a breast cancer susceptibility gene. Mutations in
PALB2 have been identified in almost all breast cancer populations studied to date, but the …

Loss-of-function mutations in PALB2 are associated with an increased risk of breast cancer,
with recent data showing that female breast cancer risks for PALB2 mutation carriers are …